Pyridoxamine improves survival and limits cardiac dysfunction after MI

Advanced glycation end products (AGEs) play a key role in the progression of heart failure. Whether treatments limiting AGEs formation would prevent adverse left ventricular remodeling after myocardial infarction (MI) remain unknown. We investigated whether pyridoxamine (PM) could limit adverse card...

Descripción completa

Detalles Bibliográficos
Autores principales: Deluyker, Dorien, Ferferieva, Vesselina, Driesen, Ronald B., Verboven, Maxim, Lambrichts, Ivo, Bito, Virginie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700185/
https://www.ncbi.nlm.nih.gov/pubmed/29167580
http://dx.doi.org/10.1038/s41598-017-16255-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700185/
https://www.ncbi.nlm.nih.gov/pubmed/29167580
http://dx.doi.org/10.1038/s41598-017-16255-y

Ejemplares similares